In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of ImmunityBio Inc (NASDAQ: IBRX) was $1.98 for the day, down -2.94% from the previous closing price of $2.04. In other words, the price has decreased by -$2.94 from its previous closing price. On the day, 10.93 million shares were traded. IBRX stock price reached its highest trading level at $2.05 during the session, while it also had its lowest trading level at $1.97.
Ratios:
Our analysis of IBRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.77.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 1950231040 and an Enterprise Value of 2554616064. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.62. Its current Enterprise Value per Revenue stands at 30.944 whereas that against EBITDA is -10.429.
Stock Price History:
The Beta on a monthly basis for IBRX is -0.11, which has changed by -0.2062257 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $4.27, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -10.52%, while the 200-Day Moving Average is calculated to be -21.80%.
Shares Statistics:
IBRX traded an average of 11.07M shares per day over the past three months and 15680460 shares per day over the past ten days. A total of 984.97M shares are outstanding, with a floating share count of 330.78M. Insiders hold about 66.42% of the company’s shares, while institutions hold 14.61% stake in the company. Shares short for IBRX as of 1765756800 were 109024436 with a Short Ratio of 9.85, compared to 1763078400 on 81064526. Therefore, it implies a Short% of Shares Outstanding of 109024436 and a Short% of Float of 32.950002.
Earnings Estimates
. The current rating of ImmunityBio Inc (IBRX) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.07 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.35 and -$0.47 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.26, with 3.0 analysts recommending between -$0.24 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $40.83M to a low estimate of $34M. As of. The current estimate, ImmunityBio Inc’s year-ago sales were $7.55MFor the next quarter, 5 analysts are estimating revenue of $39.25M. There is a high estimate of $43.5M for the next quarter, whereas the lowest estimate is $35M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $115.5M, while the lowest revenue estimate was $109M, resulting in an average revenue estimate of $110.96M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $214.08M in the next fiscal year. The high estimate is $248.7M and the low estimate is $155.83M.
